INTRODUCTION AND OBJECTIVES: Expression of androgen receptor splice variants (AR-Vs) is associated with resistance to current androgen deprivation therapies and antiandrogens. Constitutively active ARVs lack the ligand binding domain of androgen receptor (AR-LBD) which is the direct or indirect target of anti-androgens such as enzalutamide (ENZ) and abiraterone which blocks steroidogenesis. Recently the PLATO trial showed that the addition of abiraterone to ongoing ENZ did not improve progression-free survival in patients with castration resistant prostate cancer (CRPC). These data imply a limitation of combining AR-LBD targeting therapies. Therefore, novel therapeutic approaches are needed to improve the outcomes of CRPC patients. Both AR and truncated ARVs require a functional N-terminal domain (NTD) for activity and hence first-in-class antagonists of the AR NTD have been developed such as EPI-002 (ralaniten). Herein a next-generation EPI compound (EPI-7170) was evaluated as a monotherapy or in combination of ENZ in ENZ resistant prostate cancer cells that express AR-Vs.
INTRODUCTION AND OBJECTIVES:
Laser lithotripsy is widely accepted as a first-line modality for treatment of many diagnoses of urinary tract stones. The de facto gold standard laser source for lithotripsy is a Ho:YAG laser emitting at the wavelength of 2.10 µm. Recently, a novel SuperPulse Tm fiber laser emitting at 1.94 µm has been introduced for this purpose. In this work, we evaluated performance of the SuperPulse Tm Fiber Laser system in a prospective clinical study.
METHODS: SuperPulse Tm fiber laser has been cleared for clinical use by the Ministry of Health of Russian Federation. The study protocol has been approved by the institutional Ethical Review Board. SuperPulse Tm fiber laser system capable of operation with up to 40 W average power, 0.025e6 J pulse energy and 1600 Hz rep rate was used in this study. The study is on-going. Up to October 2018, total of 214 subjects (age range 19-83) have been enrolled into the study and total of 238 stones have been surgically treated with the device. Routine preoperative exam included multispiral CT (MCT) scan with the evaluation of stone density and location. Total procedure time, laser on time, stone extraction (when applicable) time were assessed. Control exam with kidney MCT was provided 30 days after operation.
RESULTS: Stone free-rates (no residual fragments) were 94% for kidney stones, 96% for ureter stones and 100% for bladder stones 30 days post treatment. On the dataset obtained and analyzed so far, the operation time and the laser on time varied between 4 to 38 min and 12 s to 14.4 min, respectively. No accidental damage of soft tissues was observed. The post-operative hospital stay time was 2.4 days on average. Optimal parameters in this study were found to be 0.1e0.2 J and rep rate 100e300 Hz for fine dusting and pop corning, 0.2e0.5 J and 50e150 Hz for dusting and 1e5 J and 10 to 40 Hz for fragmentation.
CONCLUSIONS: Data available so far indicate that SuperPulse Thulium fiber laser is efficacious and safe for lithotripsy. Longer-term follow ups are necessary to validate this conclusion.
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V01-02 COMPREHENSIVE CLINICAL STUDY OF SUPER PULSE TM FIBER LASER FOR TREATMENT OF STONE DISEASE
INTRODUCTION AND OBJECTIVES:
Recently, SuperPulse Thulium (Tm) fiber laser (NPO IRE-Polus) with wavelength of 1.94 µm was introduced as a promising lithotripsy tool. In preclinical study, we have found its efficacy to be higher than the leading Ho:YAG laser for fragmentation (x1.7 times) and dusting (x2.3 to 4 times) for equal energy and repetition rate settings. In this work, we report results of the on-going clinical study aimed at comprehensive evaluation of safety and efficacy of the new laser.
METHODS: The SuperPulse Tm fiber laser device has been cleared for clinical use by the Ministry of Health of Russian Federation and the protocol has been approved by the institutional Ethical Review committee. We prospectively analyzed 268 patients (173 kidney, 80 ureteral, 15 bladder stones) who underwent SuperPulse Tm fiber laser lithotripsy. Stone size, its density, operative and aser on time (LOT) were measured. Based on surgeon's feedback, retropulsion and intraoperative visibility were assessed.
RESULTS: For kidney stones, the average size was 11.4 mm (7e25 mm), for ureteral stones 7.6 mm (3e18 mm), for bladder stones 22.2 mm (9e36 mm). The average stone density for kidney stones was 987 HU (330e1960 HU), for ureteral stones -995 HU (460e1700 HU), for bladder stones 980 HU (860e1050 HU). The average time to complete renal stone fragmentation (to dust or small fragments) was 27.2 min, for ureteral stones 17.1 min, for bladder stones 19 min. LOT was 24.3; 12.7 and 14.5 min for kidney, ureter and bladder stones, respectively. The retropulsion was insignificant in all cases with energy level less than 0.5 J.
